TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma
Abstract Background Urothelial carcinoma (UC) is the ninth most commonly diagnosed cancer worldwide, with a 3.8/1 male to female ratio. Platinum-based chemotherapy is the first line standard of care for fit patients with advanced UC. However, despite a response rate (RR) for approximately half of pa...
Main Authors: | Elodie Coquan, Bénédicte Clarisse, Justine Lequesne, Pierre-Emmanuel Brachet, Zoé Nevière, Emeline Meriaux, Isabelle Bonnet, Marie Castera, Nicolas Goardon, Jeremy Boutrois, Romain Travers, Florence Joly, Jean-Michel Grellard, Antoine Thiery-Vuillemin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-11-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-022-10216-z |
Similar Items
-
Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial
by: Elodie Coquan, et al.
Published: (2024-02-01) -
CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure
by: Elodie Coquan, et al.
Published: (2021-09-01) -
885 Characterization of the tumor microenvironment in advanced breast cancer patients treated with talazoparib followed by combination of talazoparib and avelumab
by: Edward T Richardson, et al.
Published: (2023-11-01) -
PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
by: Stephanie Jonuscheit, et al.
Published: (2021-05-01) -
Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer According to Somatic Damage DNA Repair Gene Alterations
by: Zoé Neviere, et al.
Published: (2022-04-01)